Therapeutic agent for nervous system disease

Patent metadata

Field	Value
Publication number	US-11679122-B2
Application number	US-202217748553-A
Country	US
Kind code	B2
Filing date	May 19, 2022
Priority date	Dec 21, 2017
Publication date	Jun 20, 2023
Grant date	Jun 20, 2023

Abstract

An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.

First claim

The invention claimed is:

1. A method of promoting M2 macrophage/microglia induction, inhibiting M1 macrophage/microglia induction, and/or reducing the ratio of M1 macrophage/microglia to M2 macrophage/microglia in a patient in need thereof, the method comprising administering an agent comprising an effective amount of vitamin B 12 to the patient to promote M2 macrophage/microglia induction, inhibit M1 macrophage/microglia induction, and/or reduce the ratio of M1 macrophage/microglia to M2 macrophage/microglia.

2. The method according to claim 1 , wherein the vitamin B 12 is at least one selected from the group consisting of methylcobalamin, cyanocobalamin, hydroxocobalamin, sulfitocobalamin, adenosylcobalamin, and salts thereof.

3. The method according to claim 1 , wherein the vitamin B 12 is methylcobalamin.

4. The method according to claim 1 , wherein the agent is administered to the patient continuously for a period of time.

5. The method according to claim 1 , wherein the agent is administered to the patient by intravenous drip infusion.

Assignees

• Univ Osaka
• Nippon Zoki Pharmaceutical Co

Inventors

• Tanaka Hiroyuki
• Yoshikawa Hideki
• Mochizuki Hideki
• Murase Tsuyoshi
• Sasaki Tsutomu
• Baba Kousuke
• Iwahashi Toru
• Naiki Mitsuru

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K31/714 Primary

  Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title